Gustave Roussy is the first leader cancer-research hospital in Europe and ranked among the top 5 best specialized hospitals in the world. It is a centre for high quality patient care, research and teaching. It is highly-known for the treatment of: skin cancers like melanoma, breast cancer, and lung cancer.

There are 457 beds in Institut Gustave Roussy; Dermatologie.

During the past decade, Institut Gustave Roussy; Dermatologie conducted 5 clinical trials. In the 10-year time frame, 5 clinical trials started and 2 clinical trials were completed, i.e. on average, 40% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 2 clinical trials were completed. i.e. 200% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Institut Gustave Roussy; Dermatologie" are "Melanoma" (2 trials), "Metastatic Melanoma" (2 trials) and "Advanced BRAFV600 Wild-type Melanoma" (1 trials). Many other conditions were trialed in "Institut Gustave Roussy; Dermatologie" in a lesser frequency.

Most popular intervention types in "Institut Gustave Roussy; Dermatologie" are "Drug" (5 trials). Other intervention types were less common.

The name of intervention was led by "Cobimetinib" (4 trials), "Atezolizumab" (3 trials), "Vemurafenib" (3 trials), "Pembrolizumab" (2 trials) and "Atezolizumab Placebo" (1 trials). Other intervention names were less common.

The vast majority of trials in "Institut Gustave Roussy; Dermatologie" are 5 trials for "All" genders.

Currently, there are NaN active trials in "Institut Gustave Roussy; Dermatologie". undefined are not yet recruiting, undefined are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Institut Gustave Roussy; Dermatologie, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Institut Gustave Roussy; Dermatologie, 1 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".